Genetic Polymorphisms of Vascular Endothelial Growth Factor (VEGF) Associated with Gastric Cancer Recurrence After Curative Resection with Adjuvant Chemotherapy

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2019 May 24

PMID 31117964

Citations 11

Authors

Yeon-Ji Kim

Woo Chul Chung

Kyong-Hwa Jun

Hyung-Min Chin

Affiliations

Soon will be listed here.

Abstract

Background: The relationship between polymorphisms in vascular endothelial growth factor (VEGF) and gastric cancer is still inconclusive. We investigated whether there is an association between VEGF genetic polymorphisms and risk of gastric cancer, and evaluated the recurrence of advanced gastric cancer after curative resection with adjuvant chemotherapy according to VEGF genetic polymorphisms.

Methods: The association of functional single nucleotide polymorphisms (SNPs) of the VEGF gene (+936C > T, - 634G > C, - 2578C > A, + 1612G > A) were evaluated. Genotypes were determined by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis. A total of 151 patients with gastric cancer were enrolled, and the control group consisted of 413 individuals with esophago-gastroduodenoscopy who were randomly selected through health screening. All of the enrolled patients had curative resections with completion of adjuvant capecitabine and oxaliplatin combination chemotherapy and the initial metastatic cases were excluded. During the regular follow-up protocol, the episodes of the recurrence were documented and the specific genotype and allelic frequencies were evaluated.

Results: As for the cancer risk, there were no significant differences in specific genotypes and allelic frequencies. The mean follow-up period was 28.82 ± 30.92 (12 ~ 72) months and the recurrence rate was 28.3%. In the patients carrying the 936-C allele, the recurrence rate of gastric cancer was high (P = 0.02). Disease-free interval was significantly different between the patients carrying the 936-CC and 936-CT/TT genotype (P = 0.02).

Conclusions: VEGF 936-C allele is associated with poor prognosis, but not risk of gastric cancer. In the patients carrying the 936-C allele, more potent adjuvant treatment would be considered.

Citing Articles

Lack of association between the -2549 insertion/deletion variant of vascular endothelial growth factor and coronary artery disease in the Turkish population.

Yigit S, Nursal A, Celik A, Aci R, Askeroglu E Rev Assoc Med Bras (1992). 2024; 70(10):e20240333.

PMID: 39536247 PMC: 11554327. DOI: 10.1590/1806-9282.20240333.

Association analysis of Vascular Endothelial Growth Factor-A (VEGF-A) polymorphism in rheumatoid arthritis using computational approaches.

Ahmed I, John P, Bhatti A Sci Rep. 2023; 13(1):21957.

PMID: 38081836 PMC: 10713577. DOI: 10.1038/s41598-023-47780-8.

The Relation of VEGFA, VEGFR2, VEGI, and HIF1A Genetic Variants and Their Serum Protein Levels with Breast Cancer in Egyptian Patients.

Abdelgalil A, Monir R, Elmetwally M, Ghattas M, Bazeed F, Mesbah N Biochem Genet. 2023; 62(1):547-573.

PMID: 37392242 DOI: 10.1007/s10528-023-10419-4.

Meza-Alvarado J, Page R, Mallard B, Bromhead C, Palmer B Front Cardiovasc Med. 2023; 10:1190513.

PMID: 37288254 PMC: 10242119. DOI: 10.3389/fcvm.2023.1190513.

Genetic Polymorphisms of Vascular Endothelial Growth Factor in Neonatal Pathologies: A Systematic Search and Narrative Synthesis of the Literature.

Hasmasanu M, Procopciuc L, Matyas M, Zonda G, Zaharie G Children (Basel). 2023; 10(4).

PMID: 37189993 PMC: 10136505. DOI: 10.3390/children10040744.

References

Renner W, Kotschan S, Hoffmann C, Obermayer-Pietsch B, Pilger E . A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J Vasc Res. 2001; 37(6):443-8. DOI: 10.1159/000054076. View

Cooper B, Ritchie J, Broghammer C, Coffin J, Sorosky J, Buller R . Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer. Clin Cancer Res. 2002; 8(10):3193-7. View

Ferrara N, Gerber H, LeCouter J . The biology of VEGF and its receptors. Nat Med. 2003; 9(6):669-76. DOI: 10.1038/nm0603-669. View

Krippl P, Langsenlehner U, Renner W, Yazdani-Biuki B, Wolf G, Wascher T . A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk. Int J Cancer. 2003; 106(4):468-471. DOI: 10.1002/ijc.11238. View

Konno H, Ohta M, Baba M, Suzuki S, Nakamura S . The role of circulating IL-8 and VEGF protein in the progression of gastric cancer. Cancer Sci. 2003; 94(8):735-40. PMC: 11160261. DOI: 10.1111/j.1349-7006.2003.tb01511.x. View

Yamamori M, Sakaeda T, Nakamura T, Okamura N, Tamura T, Aoyama N . Association of VEGF genotype with mRNA level in colorectal adenocarcinomas. Biochem Biophys Res Commun. 2004; 325(1):144-50. DOI: 10.1016/j.bbrc.2004.10.005. View

Koukourakis M, Papazoglou D, Giatromanolaki A, Bougioukas G, Maltezos E, Sivridis E . VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer. Lung Cancer. 2004; 46(3):293-8. DOI: 10.1016/j.lungcan.2004.04.037. View

Jin Q, Hemminki K, Enquist K, Lenner P, Grzybowska E, Klaes R . Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis. Clin Cancer Res. 2005; 11(10):3647-53. DOI: 10.1158/1078-0432.CCR-04-1803. View

Tzanakis N, Gazouli M, Rallis G, Giannopoulos G, Papaconstantinou I, Theodoropoulos G . Vascular endothelial growth factor polymorphisms in gastric cancer development, prognosis, and survival. J Surg Oncol. 2006; 94(7):624-30. DOI: 10.1002/jso.20619. View

10.

Kim J, Sohn S, Chae Y, Cho Y, Bae H, Yan G . Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with gastric cancer. Ann Oncol. 2007; 18(6):1030-6. DOI: 10.1093/annonc/mdm085. View

11.

Barry Delongchamps N, Peyromaure M . The role of vascular endothelial growth factor in kidney and prostate cancer. Can J Urol. 2007; 14(5):3669-77. View

12.

Pander J, Gelderblom H, Guchelaar H . Pharmacogenetics of EGFR and VEGF inhibition. Drug Discov Today. 2007; 12(23-24):1054-60. DOI: 10.1016/j.drudis.2007.10.016. View

13.

Ke Q, Liang J, Wang L, Hu Z, Jin G, Zhou Y . Potentially functional polymorphisms of the vascular endothelial growth factor gene and risk of gastric cancer. Mol Carcinog. 2008; 47(8):647-51. DOI: 10.1002/mc.20435. View

14.

Bae S, Ahn D, Hong S, Kang H, Hwang S, Oh D . Gender-specific association between polymorphism of vascular endothelial growth factor (VEGF 936C>T) gene and patients with stomach cancer. Yonsei Med J. 2008; 49(5):783-91. PMC: 2615376. DOI: 10.3349/ymj.2008.49.5.783. View

15.

Tahara T, Arisawa T, Shibata T, Nakamura M, Yamashita H, Yoshioka D . Effect of polymorphisms in the 3'-untranslated region (3'-UTR) of VEGF gene on gastric pre-malignant condition. Anticancer Res. 2009; 29(2):485-9. View

16.

Tahara T, Shibata T, Nakamura M, Yamashita H, Yoshioka D, Hirata I . Effect of polymorphisms in the 3' untranslated region (3'-UTR) of vascular endothelial growth factor gene on gastric cancer and peptic ulcer diseases in Japan. Mol Carcinog. 2009; 48(11):1030-7. DOI: 10.1002/mc.20554. View

17.

Alabi A, Suppiah A, Madden L, Monson J, Greenman J . Preoperative serum vascular endothelial growth factor-a is a marker for subsequent recurrence in colorectal cancer patients. Dis Colon Rectum. 2009; 52(5):993-9. DOI: 10.1007/DCR.0b013e31819ed3bc. View

18.

Jain L, Vargo C, Danesi R, Sissung T, Price D, Venzon D . The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors. Mol Cancer Ther. 2009; 8(9):2496-508. PMC: 2751847. DOI: 10.1158/1535-7163.MCT-09-0302. View

19.

Elito Jr J, Daher S, Fernandes da Silva M, Marconi N, Pendeloski K, Moron A . Association study of vascular endothelial growth factor and polymorphisms of its gene with ectopic pregnancy. Am J Reprod Immunol. 2009; 63(2):120-5. DOI: 10.1111/j.1600-0897.2009.00769.x. View

20.

Steffensen K, Waldstrom M, Brandslund I, Jakobsen A . The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer. Gynecol Oncol. 2010; 117(1):109-16. DOI: 10.1016/j.ygyno.2009.11.011. View